AKAN
AKAN
NASDAQ · Pharmaceuticals

Akanda Corp

$15.50
-0.51 (-3.19%)
Financial Highlights (FY 2026)
Revenue
30.53M
Net Income
-149,480,499
Gross Margin
24.9%
Profit Margin
-489.6%
Rev Growth
+172.4%
D/E Ratio
0.08
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 24.9% 35.1% 35.1% 35.1%
Operating Margin -496.7% 18.3% 19.5% 18.5%
Profit Margin -489.6% 16.6% 13.3% 12.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 30.53M 777.7K 707.3K 858.5K
Gross Profit 7.61M 272.6K 247.9K 300.9K
Operating Income -151,673,020 142.4K 138.2K 159.0K
Net Income -149,480,499 128.9K 94.3K 103.5K
Gross Margin 24.9% 35.1% 35.1% 35.1%
Operating Margin -496.7% 18.3% 19.5% 18.5%
Profit Margin -489.6% 16.6% 13.3% 12.1%
Rev Growth +172.4% -2.7% +7.8% +11.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 375.1K 623.9K 606.2K 721.3K
Total Equity 4.55M 1.34M 1.23M 1.39M
D/E Ratio 0.08 0.46 0.49 0.52
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -146,527,020 197.3K 212.4K 232.8K
Free Cash Flow 80.3K 76.9K 86.9K